Medtronic's fiscal 4th-quarter sales surge nearly 60% thanks to its buyout earlier this year of Covidien, prompting the medical device company to tighten its earning forecast.
A former sales rep for Covidien's vascular business in Southern California accuses the company of firing him for blowing the whistle on an alleged kickbacks scheme.
A former sales rep for Covidien's vascular business accused the company of wrongful termination after it fired him for blowing the whistle to the FBI on an alleged kickbacks scheme.
Spectranetics says it plans to boost its R&D spend on the Stellarex drug-eluting balloon it bought from Covidien.
Spectranetics touts 2-year data from a study of the Stellarex drug-eluting balloon it bought from Covidien earlier this year.
Medtronic says it's launching a new directional atherectomy device called the HawkOne to treat peripheral artery disease.
Medtronic touts positive 3-year results for the EverFlex self-expanding stent for treating peripheral artery disease it acquired when it bought Covidien for $50 billion.
Here's a look at some of the top regulatory stories for medical device companies this week: Boston Scientific wins CE Mark, FDA nod for smaller 'leadless' ICD; FDA approves Biotronik's Eluna MRI-safe pacemaker; PAD: Medtronic wins expanded FDA nod for Protégé GPS stent; Australian PE shop acquires Simplify Medical